NCT04263831
Low Dose IL-2 for the Treatment of Crohn's Disease
Recruiting
PHASE1Ages 12–80InterventionalTreatmentBoston Children's HospitalInvestigator-initiated
~30 participants
Updated 2026-08-03 on ClinicalTrials.gov
What's tested:Interleukin-2 (aldesleukin).
At a glance
Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of subjects with serious and non-serious adverse events.
Measured over 8 weeks
+1 more outcome measured
Conditions
Where it's being run
3 sites across 2 statesMassachusetts2
New York1
Study leadership
- Scott Snapper, MD, PhD · PRINCIPAL_INVESTIGATOR · Boston Children's Hospital
- Jessica Allegretti, MD, MPH · PRINCIPAL_INVESTIGATOR · Brigham and Women's Hosptial
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of subjects with serious and non-serious adverse events.8 weeks
Enumeration of the serious and non-serious adverse events seen in the study. Enumeration of any dose limiting toxicity seen in the study.
- Maximum effective dose8 weeks
Identification of the dose cohort at which the MED occurs.